Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company focused on oncology and immunotherapy, has launched an artificial intelligence-powered GMP manufacturing services platform designed to address a critical bottleneck in biotechnology: the high cost and complexity of establishing compliant manufacturing infrastructure. The platform, announced in June, integrates Oncotelic's proprietary PDAOAI architecture with digital batch records and intelligent robotics developed in partnership with TechForce Robotics.
For emerging biotech companies, the path from discovery to clinical trials often stalls at manufacturing. Building a facility that meets Good Manufacturing Practice (GMP) standards requires significant capital, specialized expertise, and ongoing regulatory compliance. Many small firms lack the resources to build such infrastructure in-house, forcing them to rely on contract development and manufacturing organizations (CDMOs), which can be expensive and may not offer the flexibility needed for early-stage development.
Oncotelic's new platform targets these emerging biotechs, as well as cell and gene therapy developers and radiopharmaceutical manufacturers, by providing access to AI-powered GMP services without the need for in-house facilities. The platform already operates within Oncotelic's SAPU manufacturing base, where it has been used to accelerate the company's own pipeline. By offering these capabilities externally, Oncotelic positions the platform as both a pipeline accelerator and a potential new revenue stream.
The AI-driven system automates key aspects of manufacturing, including batch record management, quality control, and process monitoring, reducing the risk of human error and improving efficiency. Digital batch records ensure real-time data capture and traceability, which are essential for regulatory submissions. The integration of robotics further enhances precision and scalability, allowing for consistent production of complex biologics and cell therapies.
This launch comes as the biotech industry faces increasing pressure to reduce development timelines and costs. Manufacturing delays are a leading cause of clinical trial setbacks, particularly for advanced therapies that require specialized handling. By offering a ready-made GMP platform, Oncotelic aims to help smaller companies bypass these hurdles and move faster into clinical testing.
Investors can find the latest news and updates regarding OTLC in the company’s newsroom at https://ibn.fm/OTLC.
